Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain camera could spot which cells are causing Alzheimer's inflammation

NCT ID NCT05582200

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses special PET scans to look at two types of brain cells involved in inflammation in Alzheimer's disease. Researchers will give participants two different tracers to see microglia and astrocytes separately. The goal is to develop a method that can tell these cells apart, which could help monitor new treatments for brain inflammation. The study involves 71 people with Alzheimer's and healthy volunteers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET tracers: 11C-ER176 and 18F-SMBT1
What this could lead to
If successful, this method could help doctors see which brain cells are inflamed in Alzheimer's, making it easier to monitor new anti-inflammatory treatments.
What could go wrong
This is an early imaging study, not a treatment trial. It may not lead to direct patient benefits, and the method needs further validation before routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers and patients with Alzheimer's disease

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients with Alzheimer's disease Inclusion criteria: * Individuals of either sex, 50-90 years of age. * Meeting research criteria for AD (McKhann, Knopman et al. 2011). * With a CDR (Morris 1993) score of 1-3. * Fluent in English or Spanish. * Have sufficient communication and comprehension ability to consent to the performance of the study or have a legally authorized representative. Exclusion criteria: * Inability to undergo MRI or PET for any reason, including severe claustrophobia. * History of large stroke or brain trauma, multiple sclerosis or other brain disorder that, in the judgment of the PI may confound the study. * Pregnancy. In women in whom the possibility of pregnancy cannot be excluded, a pregnancy test must be performed on site the morning of any PET visit and a negative result together with a physician interview are required prior to the administration or any radiopharmaceutical. * Research radiation exposure greater than 50 mSv effective dose within 12 months including radiation exposure from this study. Healthy volunteers: Inclusion criteria: * Individuals of 18-90 years of age. * Negative amyloid accumulation determined by PET (only for the comparison with AD). * Fluent in English. * Have enough communication and comprehension ability to consent to the performance of the study. Exclusion criteria: * Inability to undergo MRI or PET for any reason, including severe claustrophobia. * Brain disorder, other than idiopathic headache. * Current primary Axis I or II psychiatric disorder. * Current use of psychotropic or anti-epileptic medication. * Substance abuse during the past two years. * Active cancer, metabolic encephalopathy, infection, cardiovascular disease. * Active hematological, renal, pulmonary, endocrine or hepatic disorders, except for treated thyroid disease. * Pregnancy. In women in whom the possibility of pregnancy cannot be excluded, a pregnancy test must be performed on site the morning of any PET visit and a negative result together with a physician interview are required prior to the administration or any radiopharmaceutical * Research radiation exposure greater than 50 mSv effective dose within 12 months including radiation exposure from this study. * Only for the subjects undergoing the blocked scan with selegiline: known contraindications to selegiline, including hypersensitivity to the drug and use of opioids, such as meperidine and some antidepressants such as bupropion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Houston Methodist Research Institute

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.